Thermo Fisher Scientific Inc.
TMO
$590.83
-$2.42-0.41%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/31/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.74B | 43.21B | 42.90B | 42.88B | 42.37B |
| Total Other Revenue | 1.00M | 1.00M | -- | -- | -- |
| Total Revenue | 43.74B | 43.21B | 42.90B | 42.88B | 42.37B |
| Cost of Revenue | 25.64B | 25.37B | 25.12B | 25.13B | 25.05B |
| Gross Profit | 18.10B | 17.84B | 17.77B | 17.75B | 17.32B |
| SG&A Expenses | 8.47B | 8.45B | 8.50B | 8.60B | 8.51B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -44.00M | -44.00M | -44.00M | -44.00M | 1.00M |
| Total Operating Expenses | 35.48B | 35.19B | 34.98B | 35.07B | 34.91B |
| Operating Income | 8.26B | 8.02B | 7.92B | 7.81B | 7.46B |
| Income Before Tax | 7.12B | 7.02B | 6.99B | 7.00B | 6.76B |
| Income Tax Expenses | 544.00M | 436.00M | 472.00M | 658.00M | 641.00M |
| Earnings from Continuing Operations | 6.58K | 6.58K | 6.52K | 6.34K | 6.12K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.00M | 0.00 | -4.00M | -4.00M | 14.00M |
| Net Income | 6.57B | 6.58B | 6.52B | 6.34B | 6.14B |
| EBIT | 8.26B | 8.02B | 7.92B | 7.81B | 7.46B |
| EBITDA | 11.06B | 10.90B | 10.90B | 10.92B | 10.67B |
| EPS Basic | 17.33 | 17.32 | 17.10 | 16.59 | 16.01 |
| Normalized Basic EPS | 12.94 | 12.55 | 12.30 | 12.17 | 11.53 |
| EPS Diluted | 17.31 | 17.29 | 17.05 | 16.53 | 15.95 |
| Normalized Diluted EPS | 12.92 | 12.52 | 12.26 | 12.12 | 11.49 |
| Average Basic Shares Outstanding | 1.52B | 1.52B | 1.52B | 1.53B | 1.53B |
| Average Diluted Shares Outstanding | 1.52B | 1.52B | 1.53B | 1.53B | 1.54B |
| Dividend Per Share | 1.68 | 1.64 | 1.60 | 1.56 | 1.52 |
| Payout Ratio | 9.48% | 9.26% | 9.16% | 9.20% | 9.29% |